• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

NINOMIYA KIICHIRO  二宮 貴一朗

ORCIDConnect your ORCID iD *help
… Alternative Names

Ninomiya Kiichiro  二宮 貴一朗

Less
Researcher Number 80788802
Other IDs
Affiliation (Current) 2026: 岡山大学, 医療開発領域, 助教
Affiliation (based on the past Project Information) *help 2026: 岡山大学, 医療開発領域, 助教
2022 – 2024: 岡山大学, 大学病院, 助教
2021: 岡山大学, 医歯薬学域, 助教
2019 – 2020: 岡山大学, 医歯薬学総合研究科, 助教
Review Section/Research Field
Principal Investigator
Basic Section 50020:Tumor diagnostics and therapeutics-related
Keywords
Principal Investigator
免疫療法 / biomarker / immunotherapy / CTLA-4 / 抗CTLA-4抗体 / バイオマーカー / がん免疫療法 / 分子標的治療 / Tumor mutational burden / HER2遺伝子変異 … More / Tumor Mutational Burden / HER遺伝子変異 / 非小細胞肺がん / NSCLC / ERBB2 insertion / 全エクソーム解析 / HER2 / 非小細胞肺癌 Less
  • Research Projects

    (3 results)
  • Research Products

    (5 results)
  •  脳転移制御における三次リンパ組織の役割と免疫治療標的としての可能性の解明Principal Investigator

    • Principal Investigator
      二宮 貴一朗
    • Project Period (FY)
      2026 – 2028
    • Research Category
      Grant-in-Aid for Scientific Research (C)
    • Review Section
      Basic Section 50020:Tumor diagnostics and therapeutics-related
    • Research Institution
      Okayama University
  •  Development of biomarkers for cancer immunotherapy (anti-CTLA-4 antibody) based on tumor-infiltrating lymphocytesPrincipal Investigator

    • Principal Investigator
      Ninomiya Kiichiro
    • Project Period (FY)
      2022 – 2024
    • Research Category
      Grant-in-Aid for Early-Career Scientists
    • Review Section
      Basic Section 50020:Tumor diagnostics and therapeutics-related
    • Research Institution
      Okayama University
  •  Development of innovative HER2-targeted therapy in HER2-mutant lung cancerPrincipal Investigator

    • Principal Investigator
      Ninomiya Kiichiro
    • Project Period (FY)
      2019 – 2022
    • Research Category
      Grant-in-Aid for Early-Career Scientists
    • Review Section
      Basic Section 50020:Tumor diagnostics and therapeutics-related
    • Research Institution
      Okayama University

All 2025 2024 2022

All Journal Article Presentation

  • [Journal Article] High Antigenicity for Treg Cells Confers Resistance to PD-1 Blockade Therapy via High PD-1 Expression in Treg Cells2025

    • Author(s)
      Matsuura Hiroaki、Ishino Takamasa、Ninomiya Toshifumi、Ninomiya Kiichiro、Tachibana Kota、Honobe‐Tabuchi Akiko、Muto Yoshinori、Inozume Takashi、Ueda Youki、Ohashi Kadoaki、Maeda Yoshinobu、Nagasaki Joji、Togashi Yosuke
    • Journal Title

      Cancer Science

      Volume: 116 Issue: 5 Pages: 1214-1226

    • DOI

      10.1111/cas.70029

    • Peer Reviewed / Open Access / Int'l Joint Research
    • Data Source
      KAKENHI-PROJECT-22K15607, KAKENHI-PROJECT-23K24339, KAKENHI-PROJECT-24K02459, KAKENHI-PROJECT-24K11153, KAKENHI-PROJECT-24K22071, KAKENHI-PROJECT-24K18933, KAKENHI-PROJECT-23KK0149
  • [Presentation] 肺癌における抗CTLA-4抗体が腫瘍浸潤制御性T細胞に与える影響の解明2024

    • Author(s)
      冨樫 庸介、渡部 智文、松浦 宏昌、二宮 貴一朗
    • Organizer
      第64回日本呼吸器学会学術集会
    • Invited
    • Data Source
      KAKENHI-PROJECT-22K15607
  • [Presentation] 肺癌における抗CTLA-4抗体が腫瘍浸潤制御性T細胞に与える影響の解明2024

    • Author(s)
      冨樫 庸介、渡部 智文、松浦 宏昌、二宮 貴一朗
    • Organizer
      第64回日本呼吸器学会学術講演会
    • Invited
    • Data Source
      KAKENHI-PROJECT-22K15607
  • [Presentation] HER2遺伝子異常陽性、EGFR exon20遺伝子変異陽性肺癌に対する治療開発2022

    • Author(s)
      二宮貴一朗
    • Organizer
      第19回日本臨床腫瘍学会
    • Invited
    • Data Source
      KAKENHI-PROJECT-19K16865
  • [Presentation] Development of treatment for HER2 or EGFR Exon 20 insertion mutation-driven NSCLC2022

    • Author(s)
      Kiichiro Ninomiya
    • Organizer
      JSMO2022
    • Invited
    • Data Source
      KAKENHI-PROJECT-19K16865

URL: 

Are you sure that you want to link your ORCID iD to your KAKEN Researcher profile?
* This action can be performed only by the researcher himself/herself who is listed on the KAKEN Researcher’s page. Are you sure that this KAKEN Researcher’s page is your page?

この研究者とORCID iDの連携を行いますか?
※ この処理は、研究者本人だけが実行できます。

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi